These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26176043)

  • 21. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
    Long Y; Mi Y; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
    Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
    J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus.
    Ushijima Y; Luo C; Goshima F; Yamauchi Y; Kimura H; Nishiyama Y
    Microbes Infect; 2007 Feb; 9(2):142-9. PubMed ID: 17218138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.
    Ishihara M; Seo N; Mitsui J; Muraoka D; Tanaka M; Mineno J; Ikeda H; Shiku H
    PLoS One; 2014; 9(8):e104669. PubMed ID: 25105508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C; Noonan S; Lou E; Shillitoe EJ
    Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
    Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes simplex virus oncolytic vaccine therapy in melanoma.
    Sivendran S; Pan M; Kaufman HL; Saenger Y
    Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current state of oncolytic virotherapy in Japan].
    Nakamori M; Yamaue H
    Gan To Kagaku Ryoho; 2013 May; 40(5):553-8. PubMed ID: 23863576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
    Taguchi S; Fukuhara H; Todo T
    Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.